Abstract
Proof-of-concept has long been gained from both Huntington's disease (HD) animal models and pilot clinical trials that transplantation of fetal striatal tissue has the potential to offer a substitutive therapy to HD patients (Peschanski et al., 1995; Bachoud-Levi et al., 2006; Reuter et al., 2008; Paganini et al., 2014). Nonetheless, in the stem cell era, the body of knowledge so far obtained from fetal tissue as cell source may well be handed over to the clinical exploitation of neural stem cells (Tabar and Studer, 2014).
Highlights
Reviewed by: Anselme Louis Perrier, Institut National de la Santé et de la Recherche Médicale, France
A commentary on Differentiation of pluripotent stem cells into striatal projection neurons: a pure medium-sized spiny projection neurons (MSN) fate may not be sufficient by Reddington, A
Loss of DARPP-32 medium-sized spiny projection neurons (MSN) in the striatum is a hallmark of Huntington’s disease (HD)
Summary
Reviewed by: Anselme Louis Perrier, Institut National de la Santé et de la Recherche Médicale, France. A commentary on Differentiation of pluripotent stem cells into striatal projection neurons: a pure MSN fate may not be sufficient by Reddington, A.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
